Previous close | 0.9000 |
Open | 0.9000 |
Bid | 0.4500 |
Ask | 1.2000 |
Strike | 175.00 |
Expiry date | 2024-09-20 |
Day's range | 0.9000 - 0.9000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.